Objective:

To investigate the potential of delivering a neuroprotective retinal therapy via eye drops instead of injections.

Key Findings:

• Topical JGRi1 reached the mouse retina and mitigated degeneration in two models of retinal injury.
• The peptide preserved retinal ganglion cell survival and reduced apoptosis in both experimental models.
• JGRi1 decreased glutamate levels and JNK phosphorylation, and reduced SNARE complex formation.
• The treatment also suggested a reduction in microglial infiltration, indicating potential modulation of inflammatory responses.

Interpretation:

The study presents a novel approach to neuroprotection by targeting a specific excitotoxic mechanism rather than broadly blocking NMDA receptors.

Limitations:

• The study was conducted in animal models and does not address chronic conditions.
• No randomization or blinding were performed.
• Long-term functional vision outcomes and pharmacokinetics in humans were not evaluated.

Conclusion:

JGRi1 represents a promising topical therapy that could lead to new treatment avenues for retinal neurodegenerative diseases.